Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes

被引:30
|
作者
Humar, Abhinav [1 ]
Crotteau, Shaina [1 ]
Gruessner, Angelika [1 ]
Kandaswamy, Raja [1 ]
Gruessner, Rainer [1 ]
Payne, William [1 ]
Lake, John [1 ]
机构
[1] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA
关键词
immunosuppression; liver transplant; post-transplant diabetes; steroid avoidance;
D O I
10.1111/j.1399-0012.2007.00683.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Steroid minimization regimens have become increasingly popular for kidney transplant recipients. We studied outcomes for liver transplant recipients with a regimen using rapid discontinuation of prednisone (RDP). Results: The study group consisted of 83 recipients transplanted between June 2004 and January 2006. Immunosuppression consisted of tacrolimus, MMF, and two doses of basiliximab with six d of steroids. Patients with underlying autoinunune disorders (PSC, autoimmune hepatitis) were not included as they were maintained on steroids. The control group consisted of 83 recipients transplanted between January 2002 and May 2004. Immunosuppression consisted of tacrolimus, MMF and steroids, with no antibody induction. Mean MELD score at time of transplant was significantly higher in the steroid free group vs. the control group (28 vs. 23, p = 0.02); mean donor age was also higher (42 vs. 37 yr, p = 0.02). Other characteristics including recipient age, cold ischemic time, donor source, and cause of liver disease were similar (p = ns). Mean length of follow-up was 16.1 months in the RDP group and 32 months in the control group; a minimum of six months follow up was present for all patients. Patient and graft survival rates were not statistically different in the two groups (p = ns). Biopsy proven rejection was low in both groups and not significantly different (at one yr post-transplant 11% in the RDP group vs. 12% in control, p = 0.53). Based on protocol biopsy data, histologic recurrence of hepatitis C was demonstrated in 56% of the control group hepatitis C positive recipients vs. 39% in the RDP group (p = 0.05). There was a significantly lower incidence of post-transplant diabetes (PTDM) in the RDP vs. control group (at 6 months post-transplant 12% vs. 32%. p = 0.004). Conclusions: Rapid discontinuation of prednisone in liver transplant recipients is not associated with an increased risk of rejection, and may be associated with lower morbidity, especially PTDM and hepatitis C recurrence.
引用
收藏
页码:526 / 531
页数:6
相关论文
共 50 条
  • [1] Impact of Hepatitis C Viremia on Post-Transplant Diabetes Mellitus Development in Liver Transplant Recipients.
    Klein, K.
    Nelson, J.
    Crowther, B.
    Guerra, C.
    Kincaide, E.
    Speeg, K. V.
    Alkhouri, N.
    Hall, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 870 - 870
  • [2] Post-transplant diabetes mellitus and recurrent graft hepatitis in hepatitis C(+) liver transplant recipients.
    Baid, S
    Cosimi, AB
    Farrell, M
    Rubin, N
    Chung, R
    Feng, S
    Pascual, M
    TRANSPLANTATION, 2000, 69 (08) : S267 - S267
  • [3] Hepatitis C recurrence in liver transplant recipients
    Kizilisik, TA
    AlSebayel, M
    Hammad, A
    AlTraif, I
    Ramirez, CG
    Abdulla, A
    TRANSPLANTATION PROCEEDINGS, 1997, 29 (07) : 2875 - 2877
  • [4] Is diabetes a risk factor for malignancy post-transplant in liver transplant recipients?
    Congly, Stephen E.
    ANNALS OF HEPATOLOGY, 2022, 27 (03)
  • [5] Post-transplant diabetes mellitus in Canadian liver and renal transplant recipients
    Dascal, Roman
    Wiebe, Chris
    Niazi, Mina
    Worobetz, Lawrence
    Bhanji, Rahima A.
    Knowles, Cori
    Uhanova, Julia
    Peretz, David
    Faisal, Nabiha
    Minuk, Gerald Y.
    CANADIAN LIVER JOURNAL, 2022, 5 (04): : 466 - 475
  • [6] The impact of post-transplant diabetes mellitus on liver transplant outcomes
    Lieber, Sarah R.
    Lee, Ruth-Ann
    Jiang, Yue
    Reuter, Claire
    Watkins, Randall
    Szempruch, Kristen
    Gerber, David A.
    Desai, Chirag S.
    DeCherney, G. Stephen
    Barritt, A. Sidney
    CLINICAL TRANSPLANTATION, 2019, 33 (06)
  • [7] Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation
    Hori, Tomohide
    Onishi, Yasuharu
    Kamei, Hideya
    Kurata, Nobuhiko
    Ishigami, Masatoshi
    Ishizu, Yoji
    Ogura, Yasuhiro
    ANNALS OF GASTROENTEROLOGY, 2016, 29 (04): : 454 - 459
  • [8] Post-transplant eradication of hepatitis C by pre-transplant treatment in living donor liver transplant recipients.
    Halprin, A
    Trotter, JF
    Everson, GT
    Wachs, M
    Bak, T
    Kugelmas, M
    Kam, I
    HEPATOLOGY, 2001, 34 (04) : 244A - 244A
  • [9] Post-transplant lymphoproliferative disease in liver transplant recipients
    Rubio-Manzanares-Dorado, Mercedes
    Maria Alamo-Martinez, Jose
    Bernal-Bellido, Carmen
    Miguel Marin-Gomez, Luis
    Suarez-Artacho, Gonzalo
    Cepeda-Franco, Carmen
    Wang, Jize
    Angel Gomez-Bravo, Miquel
    Padillo, Javier
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2017, 109 (06) : 406 - 412
  • [10] Development of Post-Transplant DSA Following Immunosuppression Minimization/Withdrawal in Liver Transplant Recipients.
    Jucaud, V.
    Shaked, A.
    DesMarais, M.
    Sayre, P.
    Everly, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 472 - 473